Tag: Dr Kiran Mazumdar Shaw
Biocon Biologics announces positive CHMP opinion for its biosimilar to treat...
The CHMP positive opinion will be considered by the European Commission whose decision on the approval is expected by the end of September 2023
Biocon Academy holds graduation ceremony for 185 students
73% of graduating students are females; 100% placement achieved
Biocon awarded a Silver Medal by EcoVadis for its sustainability accomplishments
Overall Score of 66 puts Biocon in the 89th percentile in 2022 assessment
Biocon Biologics wins ‘ABEA : Bioprocessing Excellence in South Asia’ Award
The company garnered the maximum number of votes from among 70,000 biopharma professionals who participated in the survey
World Cancer Day: Dr Devi Shetty & Kiran Mazumdar Shaw inaugurate...
The unit will boost of CAR-T Cell Therapy & Immunotherapy and has proficient medical staff including of haemato-oncologists, BMT physicians and nursing staff.
Kiran Mazumdar Shaw leads investment in Shaili Chopra led Gytree.com
Gytree.com uses technology to provide women with an intelligent dashboard, world class experts and personalized journeys for better health outcomes.
Mapmygenome launches Genomics Experience Center in Bengaluru
Customers get access to distinctive services such as genetic tests, genetic counseling, blood tests, health screening tests, antibody tests and COVID-19 RT-PCR tests
Pharma industry reiterates its commitment to US$ 130 billon by 2030
Innovation, R&D, partnership & policy support to be key growth drivers as echoed at Global Innovation Summit-2021 organized by Indian Pharmaceutical Alliance
Biocon Biologics & Serum Institute Life Sciences announce strategic alliance
BBL will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets. SILS to receive ~15% stake in BBL at a post-money valuation of ~$4.9 billion......................
Advancements in digital technology critical to advancements in clinical trials
As per experts, the digital-enabled regulatory flexibility during the pandemic that had helped bring drugs faster to market needs to continue.....................